SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, ...

▎药明康德内容团队编辑  代谢功能障碍相关脂肪肝（MASLD）已经成为患病率不断上升的全球性健康问题，而代谢功能障碍相关的脂肪性肝炎（MASH）是MASLD更为严重的阶段，患者会出现肝脏脂质过度堆积、炎症浸润和肝细胞损伤，严重时可导致肝纤维化、肝硬化 ...

New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.

该研究揭示了SGLT2抑制剂靶向CD8+ T细胞内的酮体代谢以改善MASH的病理生理学机制，为将来SGLT2抑制剂作为“老药新用”的治疗策略提供了一个重要的科学依据。 南方医科大学南方医院张惠杰教授团队联合广东省人民医院杨魏教授及山西医科大学附属第二医院李晋 ...

New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.

A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study ...

New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

"This was the largest nationwide population-based longitudinal cohort study to investigate the association between the use of ...

A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...

A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.